By Iain Gilbert
Date: Tuesday 27 Feb 2024
(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,960.0p to 2,000.0p on Tuesday, citing more stability in its generics unit.
Berenberg said Hikma had "a solid finish to 2023" across all three of its divisions, with guidance roughly 300bp ahead of consensus group revenue...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news